Benitec FY2026 10-K: $180M Cash, Material Weakness Remediated, BB-301 Pivotal Design Discussed with FDA
BNTC sits 23% above its 52-week low of $9.85.
Summary
Benitec's FY2026 10-K confirms $180M cash, remediation of the prior material weakness, and details of the $104.5M November 2025 offering. BB-301 Cohort 2 is fully enrolled with an FDA pivotal design discussion completed.
Key Events · Earnings and Guidance · BNTC
-
Material Weakness Remediated
Management concluded the previously disclosed material weakness in share-based compensation controls was remediated as of December 31, 2025, and internal control over financial reporting is effective as of June 30, 2026.
-
FY2026 Financial Results
Net loss of $45.5M ($0.98/share) vs $37.9M ($1.05/share) in FY2025; total operating expenses rose to $51.2M from $41.8M, driven by higher share-based compensation and payroll.
-
Cash Position and Runway
$180.0M in cash and cash equivalents as of June 30, 2026, up from $97.7M a year earlier, providing runway well beyond the planned mid-2027 pivotal trial initiation.
-
November 2025 Offering Details
5,930,000 shares sold at $13.50 plus 328,889 shares from partial underwriter option exercise; total gross proceeds $104.5M, less $5.7M underwriting costs and $0.6M other costs.
Analysis · BNTC · Life Sciences
Benitec's annual report confirms the FY2026 financials already previewed in today's 8-K — a $45.5M net loss on $180M cash — but adds two material governance and financing details. First, management states the previously disclosed material weakness in share-based compensation controls was remediated as of December 31, 2025, and that internal control over financial reporting is now effective. Second, the 10-K quantifies the November 2025 capital raise: 5.9M shares at $13.50 plus a partial underwriter option exercise, totaling $104.5M in gross proceeds, alongside an untapped $75M ATM facility. The cash position funds operations well beyond the planned mid-2027 pivotal trial initiation, and the FDA Type C meeting on BB-301 pivotal design was held in Q3 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTC was trading at $12.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $415M. The 52-week trading range was $9.85 to $16.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.